Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frederick L Locke

Showing results (101-110 of 234) with videos related to

Pageof 24
Sort By:
Blood Advances|February 5, 2024
Outcomes of subsequent antilymphoma therapies after second-line axicabtagene ciloleucel or standard of care in ZUMA-7Armin Ghobadi, Javier Munoz, Jason R Westin, et al.
Frontiers in Immunology|February 15, 2021
Proceedings From the First International Workshop at Sidra Medicine: "Engineered Immune Cells in Cancer Immunotherapy (EICCI): From Discovery to Off-the-Shelf Development", 15<sup>th</sup>-16<sup>th</sup> February 2019, Doha, QatarBella Guerrouahen, Muhammad Elnaggar, Anjud Al-Mohannadi, et al.
JCI Insight|August 15, 2023
Modulating the polyamine/hypusine axis controls generation of CD8+ tissue-resident memory T cellsAya G Elmarsafawi, Rebecca S Hesterberg, Mario R Fernandez, et al.
International Journal of Radiation Oncology, Biology, Physics|June 9, 2019
Radiation Therapy as a Bridging Strategy for CAR T Cell Therapy With Axicabtagene Ciloleucel in Diffuse Large B-Cell LymphomaAustin J Sim, Michael D Jain, Nicholas B Figura, et al.
Blood Advances|October 9, 2020
Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphomaFrederick L Locke, John M Rossi, Sattva S Neelapu, et al.
Transplantation and Cellular Therapy|May 18, 2024
ACT To Sustain: Adoptive Cell Therapy To Sustain Access to Non-Commercialized Genetically Modified Cell TherapiesRebecca A Gardner, Claire White, Magdi Elsallab, et al.
Blood Advances|September 3, 2020
Venous thromboembolism associated with CD19-directed CAR T-cell therapy in large B-cell lymphomaHamza Hashmi, Abu-Sayeef Mirza, Alicia Darwin, et al.
Transplantation and Cellular Therapy|August 27, 2021
Outcomes and Utilization Trends of Front-Line Autologous Hematopoietic Cell Transplantation for Mantle Cell LymphomaPeter A Riedell, Mehdi Hamadani, Kwang W Ahn, et al.
Journal of Geriatric Oncology|September 18, 2023
Safety and efficacy of anti-BCMA CAR-T cell therapy in older adults with multiple myeloma: A systematic review and meta-analysisOthman Salim Akhtar, Ba Aqeel Sheeba, Farhan Azad, et al.
Transplantation and Cellular Therapy|May 24, 2022
Outcomes of Autologous Hematopoietic Cell Transplantation in Older Patients with Diffuse Large B-Cell LymphomaPashna N Munshi, Yue Chen, Kwang W Ahn, et al.
Pageof 24

Showing results (101-110 of 234) with videos related to

Sort By:
Pageof 24
Blood Advances|February 5, 2024
Outcomes of subsequent antilymphoma therapies after second-line axicabtagene ciloleucel or standard of care in ZUMA-7Armin Ghobadi, Javier Munoz, Jason R Westin, et al.
Frontiers in Immunology|February 15, 2021
Proceedings From the First International Workshop at Sidra Medicine: "Engineered Immune Cells in Cancer Immunotherapy (EICCI): From Discovery to Off-the-Shelf Development", 15<sup>th</sup>-16<sup>th</sup> February 2019, Doha, QatarBella Guerrouahen, Muhammad Elnaggar, Anjud Al-Mohannadi, et al.
JCI Insight|August 15, 2023
Modulating the polyamine/hypusine axis controls generation of CD8+ tissue-resident memory T cellsAya G Elmarsafawi, Rebecca S Hesterberg, Mario R Fernandez, et al.
International Journal of Radiation Oncology, Biology, Physics|June 9, 2019
Radiation Therapy as a Bridging Strategy for CAR T Cell Therapy With Axicabtagene Ciloleucel in Diffuse Large B-Cell LymphomaAustin J Sim, Michael D Jain, Nicholas B Figura, et al.
Blood Advances|October 9, 2020
Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphomaFrederick L Locke, John M Rossi, Sattva S Neelapu, et al.
Transplantation and Cellular Therapy|May 18, 2024
ACT To Sustain: Adoptive Cell Therapy To Sustain Access to Non-Commercialized Genetically Modified Cell TherapiesRebecca A Gardner, Claire White, Magdi Elsallab, et al.
Blood Advances|September 3, 2020
Venous thromboembolism associated with CD19-directed CAR T-cell therapy in large B-cell lymphomaHamza Hashmi, Abu-Sayeef Mirza, Alicia Darwin, et al.
Transplantation and Cellular Therapy|August 27, 2021
Outcomes and Utilization Trends of Front-Line Autologous Hematopoietic Cell Transplantation for Mantle Cell LymphomaPeter A Riedell, Mehdi Hamadani, Kwang W Ahn, et al.
Journal of Geriatric Oncology|September 18, 2023
Safety and efficacy of anti-BCMA CAR-T cell therapy in older adults with multiple myeloma: A systematic review and meta-analysisOthman Salim Akhtar, Ba Aqeel Sheeba, Farhan Azad, et al.
Transplantation and Cellular Therapy|May 24, 2022
Outcomes of Autologous Hematopoietic Cell Transplantation in Older Patients with Diffuse Large B-Cell LymphomaPashna N Munshi, Yue Chen, Kwang W Ahn, et al.
Pageof 24